Effect of Platelet-Activating Factor on Platelets and Vascular Endothelium

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  1989-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-2007-1002704PMID 2546255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic platelet activation by aggregates of IgG and the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine

  2004cited by this paper
• The involvement of platelets in non-thrombotic processes.

  1988cited by this paper
• Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063.

  1988cited by this paper
• The role of Ca2+ in regulating the catabolism of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in rabbit platelets.

  1987cited by this paper
• Effect of platelet-activating factor on airway vascular permeability: possible mechanisms.

  1987cited by this paper
• Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.

  1987cited by this paper
• Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers.

  1987cited by this paper
• Potentiation and inhibition by clonidine of PAF-acether-induced human platelet activation.

  1987cited by this paper
• Sphingosine inhibition of agonist-dependent secretion and activation of human platelets implies that protein kinase C is a necessary and common event of the signal transduction pathways.

  1987cited by this paper
• Evidence for a Role for Na+‐H+ Exchange in Activation of Human Platelets by PAF

  1987cited by this paper
• Effect of platelet-activating factor (PAF-acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (IL1) release and synthesis by rat spleen adherent monocytes.

  1987cited by this paper
• Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist.

  1987cited by this paper
• Paf‐acether‐induced death in mice: involvement of arachidonate metabolites and β‐adrenoceptors

  1987cited by this paper
• Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets.

  1987cited by this paper
• Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury.

  1987cited by this paper
• Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils.

  1987cited by this paper
• The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021.

  1987cited by this paper
• PAF-acether today--relevance for acute experimental anaphylaxis.

  1987cited by this paper
• Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.

  1987cited by this paper
• Intravascular release of platelet activating factor in children with sepsis.

  1987cited by this paper
• Perspectives in platelet-activating factor research.

  1987cited by this paper
• Effect of ginkgolide PAF-acether antagonists on arterial thrombosis.

  1987cited by this paper
• Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures.

  1987cited by this paper
• New horizons in platelet activating factor research

  1987cited by this paper
• GINKGOLIDES: POTENT PLATELET ACTIVATING FACTOR ANTAGONISTS ISOLATED FROM GINKGO BILOBA L.: CHEMISTRY, PHARMACOLOGY AND CLINICAL APPLICATIONS

  1987cited by this paper
• Effect of PAF-acether (platelet-activating factor) and its specific antagonist, BN 52021, on interluekin 1 (IL1) synthesis and release by rat monocytes

  1987cited by this paper
• Conformational Properties of the PAF-Acether Receptor on Platelets Based on Structure—Activity Studies

  1987cited by this paper
• Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea-pig.

  1986cited by this paper
• Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells.

  1986cited by this paper
• Platelet-activating factor (PAF-acether) induces high- and low-affinity binding of fibrinogen to human platelets via independent mechanisms.

  1986cited by this paper
• Acetyltransferase activity in human platelet microsomes and washed platelets.

  1986cited by this paper
• PAF-acether-induced synthesis of prostacyclin by human endothelial cells.

  1986cited by this paper
• Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.

  1986cited by this paper
• Kinetics of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced fibrinogen binding to human platelets.

  1986cited by this paper
• [Mammalian lignans: possible involvement in endogenous digitalis activity].

  1986cited by this paper
• Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119.

  1986cited by this paper
• Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets.

  1986cited by this paper
• Mechanism of PAF-induced platelet aggregation in man.

  1986cited by this paper
• The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021.

  1986cited by this paper
• Lignanes de mammifères: une possible implication dans l'activité digitale endogène

  1986cited by this paper
• Transient activation of the acetyltransferase necessary for paf‐acether biosynthesis in thrombin‐activated platelets

  1986cited by this paper
• Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni.

  1986cited by this paper
• /sup 3/H-PAF-acether displacement and inhibition of binding in intact human platelets by BN 52021

  1986cited by this paper
• Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes.

  1986cited by this paper
• Specific binding of [3H]dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor.

  1986cited by this paper
• PAF-acether specific binding sites: 2. Design of specific antagonists

  1986cited by this paper
• Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig.

  1986cited by this paper
• Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.

  1986cited by this paper
• Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins.

  1985cited by this paper
• Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization.

  1985cited by this paper
• The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (paf-acether) on the arterial wall.

  1985cited by this paper
• Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine.

  1985cited by this paper
• PAF-Acether May Not Mediate the Third Pathway of Platelet Aggregation since Self-Desensitization Reduces the Effects of Low Thrombin but Enhances Those of Convulxin

  1985cited by this paper
• Desensitization of human platelets by platelet activating factor.

  1985cited by this paper
• Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.

  1985cited by this paper
• Neolignans from PIPER futokadsura

  1985cited by this paper
• Platelet Membrane Potential: Simultaneous Measurement of diSC3(5) Fluorescence and Optical Density

  1985cited by this paper
• Cyclic AMP inhibits platelet activation independently of its effect on cytosolic free calcium.

  1985cited by this paper
• 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle.

  1985cited by this paper
• Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways.

  1985cited by this paper
• Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked.

  1985cited by this paper
• Phospholipid biosynthesis in human platelets. The acylation of lyso-platelet-activating factor.

  1985cited by this paper
• Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP.

  1985cited by this paper
• Prostacyclin synthesis induced in vascular cells by interleukin-1.

  1985cited by this paper
• Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets.

  1985cited by this paper
• Stimulation of high-affinity hormone-sensitive GTPase of human platelets by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphocholine (platelet activating factor).

  1985cited by this paper
• Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.

  1985cited by this paper
• Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product.

  1985cited by this paper
• Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.

  1985cited by this paper
• Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine.

  1984cited by this paper
• Dissociation between inhibition of phospholipid methylation and production of PAF-acether by rabbit platelets

  1984cited by this paper
• Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines.

  1984cited by this paper
• Platelet-activating factor and structurally related ether-lipids

  1984cited by this paper
• Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine.

  1984cited by this paper
• Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets.

  1984cited by this paper
• Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets.

  1984cited by this paper
• Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin.

  1984cited by this paper
• Inflammatory characteristics of platelet activating factor (PAF‐acether) in human skin

  1984cited by this paper
• Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor.

  1984cited by this paper
• Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change.

  1984cited by this paper
• PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils.

  1984cited by this paper
• VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).

  1984cited by this paper
• Paf-acether formation and arachidonic acid freeing from platelet ether-linked glyceryl-phosphorylcholine.

  1984cited by this paper
• Conversion of 1-alkyl-2-acetyl-sn-glycerols to platelet activating factor and related phospholipids by rabbit platelets.

  1984cited by this paper
• STRUCTURAL ANALOGS OF PAF‐ACETHER. I. RAC‐ACETYLOXYDOCOSYL PHOSPHORYLCHOLINES

  1984cited by this paper
• Evaluation of Dose and Route Effects of Platelet Activating Factor-Induced Extravasation in the Guinea Pig

  1984cited by this paper
• Mechanisms of platelet activation: role of methylation reactions

  1984cited by this paper
• Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor

  1984cited by this paper
• Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.

  1984cited by this paper
• [Platelet aggregation and PAF-acether. Pharmacologic interference].

  1984cited by this paper
• Triggering by Paf‐acether and adrenaline of cyclo‐oxygenase‐independent platelet aggregation

  1984cited by this paper
• Effect of platelet activating factor on endothelial permeability to plasma macromolecules.

  1984cited by this paper
• Characteristics of the binding of platelet-activating factor to platelets of different animal species.

  1984cited by this paper
• Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine.

  1984cited by this paper
• The release of platelet-activating factor from human endothelial cells in culture.

  1983cited by this paper
• Phospholipid-induced human platelet activation: effects of calcium channel blockers and calcium chelators.

  1983cited by this paper
• Platelet products and vascular PGI2 production.

  1983cited by this paper
• Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin.

  1983cited by this paper
• Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.

  1983cited by this paper
• Calmodulin antagonists inhibit aggregation of human, guinea pig and rabbit platelets induced with platelet activating factor

  1983cited by this paper

• PURIFICATION AND CHARACTERIZATION OF BLOOD ASPIRIN HYDROLASES

  2012cites this paper
• Ureases de plantas e de bactérias : estudos funcionais e propriedades biológicas independentes da atividade enzimática

  2007cites this paper
• Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis.

  2007cites this paper
• Bacillus pasteurii urease shares with plant ureases the ability to induce aggregation of blood platelets.

  2006cites this paper
• Actions of nitric oxide , estrogen , platelet activating factor and vasopressin on cardiovascular defense in rats

  2005cites this paper
• The Relationship of Haemostatic System to the Vessel Wall, Thromboembolism, Atherosclerosis from Pathogenesis and Laboratory Standpoints.

  2002cites this paper
• The role of reactive oxygen species in traumatic brain injury : Experimental studies in the rat

  2001cites this paper
• Electronegative LDL From Normolipemic Subjects Induces IL-8 and Monocyte Chemotactic Protein Secretion by Human Endothelial Cells

  2000cites this paper
• Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations

  2000cites this paper
• Mediators of restenosis.

  1998cites this paper
• Platelet-Activating Factor Stimulates Interleukin-6 Production by Human Endothelial Cells and Synergizes with Tumor Necrosis Factor for Enhanced Production of Granulocyte-Macrophage Colony Stimulating Factor

  1997cites this paper
• Adhesion-independent synergy of monocytes and endothelial cells in cytokine production: regulation of IL-6 and GM–CSF production by PAF

  1996cites this paper
• Platelet-activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury.

  1995cites this paper
• Nitric oxide and anti-cancer therapy.

  1995cites this paper
• Characterization of platelet-activating factor synthesis in glomerular endothelial cell lines.

  1994cites this paper
• Antibodies Against Platelet-Activating Factor in Patients with Antiphospholipid Antibodies

  1994cites this paper
• Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion.

  1992cites this paper
• Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175).

  1992cites this paper
• Sex hormones and atherosclerosis

  1991cites this paper